Journal: Nature Communications
Article Title: Targeting the UFL1-AKT cascade suppresses triple-negative breast cancer progression
doi: 10.1038/s41467-026-68493-2
Figure Lengend Snippet: a , b TNBC patient-derived xenografts (PDXs) were subcutaneously implanted into nude mice. Saline, PDAU or NP (15 mg/kg) was injected intraperitoneally every 2 days when tumor volume reached 100 mm 3 . Mice were then treated with saline or cisplatin (5 mg/kg weekly, n = 6). Tumors were collected ( a ), and tumor weights were measured ( b ). Results represent the mean ± SD from six mice. c Cell lysates from PDXs treated with saline, PDAU or NP were subjected to immunoprecipitation with IgG, anti-UFL1 antibodies. The immunoprecipitates were blotted with the indicated antibodies. d Cell lysates from PDXs treated with saline, PDAU or NP were subjected to western blot with the indicated antibodies. e Representative images of H&E, Ki67 and cleaved PARP1 staining in xenograft models from ( a ). Scale bars, 50 μm. Data were analyzed by two-sided one-way ANOVA in ( b ). Source data are provided as a Source Data file.
Article Snippet: Anti-UFL1 (A303-456A, dilution: 1:1000) antibodies were purchased from BETHYL.
Techniques: Derivative Assay, Saline, Injection, Immunoprecipitation, Western Blot, Staining